The Relationship between the Degrees of Clinical Manifestations and IgG Antibodies When a Confirmed COVID-19 Recovered Patient at the M. Yunus Hospital and The Harapan and Doa Hospital of Bengkulu City in 2020
DOI:
https://doi.org/10.70135/seejph.vi.882Keywords:
COVID-19, Clinical manifestations, IgG, Antibody, Recovered PatientAbstract
Background: COVID-19, or coronavirus disease, was declared a pandemic by the WHO in 2020. Coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for this disease. The antibodies that the human body makes in reaction to a viral infection include IgM and IgG. The body will display different clinical indications according on how effectively it generates antibodies. Investigate the relationship between COVID-19 patients' clinical manifestations and their levels of IgG Anti-SARS-Cov-2 antibodies in Bengkulu City in 2020. The severity of clinical signs and symptoms during the sickness influences the level of antibody response generated. Methods: Descriptive research methodologies are utilized in this study, which is a retrospective. The sample strategy employed was consecutive sampling with non-probability sampling. The level of clinical manifestation of COVID-19 patients is established by the Indonesian Ministry of Health using its 2021 categorization. When looking for a connection between the two variables, the Pearson correlation test was used. Results: The research methods used in this study are descriptive and are structured like a retrospective. A non-probability sampling strategy based on the progressive sampling method was used to collect the samples. The Indonesian Ministry of Health will categorize COVID-19 patients in 2021 based on their clinical manifestation level. To look at the link between the two variables, we used the Pearson correlation test. Conclusion: Levels of IgG anti-SARS-Cov-2 antibodies and clinical symptoms in COVID-19 patients who have recovered in Bengkulu City are linked.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.